Disease · MONDO_0015914

primary orthostatic hypotension

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. primary orthostatic hypotension. Diseases, record MONDO_0015914. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015914

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: primary orthostatic hypotension; Open Targets
Open Targets ID: MONDO_0015914; Open Targets
Orphanet: ORPHA:182058; Orphanet
Highest stage of its drugs: Approval, for 1 of its 8 drugs, from TTD; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DROXIDOPA	CHEMBL2103827	Small molecule	Approval	TTD	6	5	5	Drugs and targets
AMPRELOXETINE	CHEMBL4297646	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
LEVODOPA	CHEMBL1009	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ATOMOXETINE	CHEMBL641	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MIDODRINE	CHEMBL1201212	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
MELATONIN	CHEMBL45	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
YOHIMBINE	CHEMBL15245	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBON DIOXIDE	CHEMBL1231871	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets13

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor	2	Adrenergic receptor agonist; Adrenergic receptor alpha-1 agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	2	Norepinephrine transporter inhibitor	Phase 3	https://conductscience.org/library/genes/6530	Drugs and targets
ADRA2A	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
ADRB1	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/154	Drugs and targets
ADRB3	Adrenergic receptor	1	Adrenergic receptor agonist	Approval	https://conductscience.org/library/genes/155	Drugs and targets

1 to 10 of 13

See all 13 targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00782340	A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa	Phase 3	263	2014-05-16	Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency	DROXIDOPA	Open Targets' reading of its record	ClinicalTrials.gov
NCT01176240	A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease	Phase 3	225	2014-05-20	Orthostatic Hypotension, Parkinson's Disease	DROXIDOPA	Open Targets' reading of its record	ClinicalTrials.gov
NCT03829657	Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure	Phase 3	203	2023-01-20	Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)	AMPRELOXETINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03750552	Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure	Phase 3	195	2022-09-14	Symptomatic Neurogenic Orthostatic Hypotension	AMPRELOXETINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00633880	Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)	Phase 3	181	2014-05-20	Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency	DROXIDOPA	Open Targets' reading of its record	ClinicalTrials.gov
NCT04095793	Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure	Phase 3	110	2022-11-30	Symptomatic Neurogenic Orthostatic Hypotension	AMPRELOXETINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01927055	A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy	Phase 3	61	2016-01-08	Symptomatic Neurogenic Orthostatic Hypotension, Parkinson's Disease, Multiple Systems Atrophy, Pure Autonomic Failure, Dopamine Beta Hydroxylase Deficiency	DROXIDOPA	Open Targets' reading of its record	ClinicalTrials.gov
NCT05487300	Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease	Phase 2/3	40	2024-12-05	Parkinson Disease, Orthostatic Hypotension	LEVODOPA	Open Targets' reading of its record	ClinicalTrials.gov
NCT00004268	Phase II Study of Midodrine for Neurogenic Orthostatic Hypotension	Phase 2	300		Orthostatic Hypotension	MIDODRINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02316821	The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study	Phase 2	216		Chronic Kidney Disease, Type 2 Diabetes	ATOMOXETINE	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Droxidopa vs Placebo: serious adverse events	5 of 114	4 of 108	222	NCT01176240	Trial comparisons
Ampreloxetine vs Placebo: deaths from any cause	0 of 96	0 of 90	186	NCT03750552	Trial comparisons
Ampreloxetine vs Placebo: serious adverse events	4 of 96	2 of 90	186	NCT03750552	Trial comparisons
Ampreloxetine vs Placebo: Number of Participants Who Experienced at Least One Fall	33 of 93	22 of 90	183	NCT03750552	Trial comparisons
Ampreloxetine vs Placebo: Number of Participants Who Experienced an Improvement From Baseline in Patient Global Impression of Change (PGI-C) Score at Week 4	49 of 91	45 of 87	178	NCT03750552	Trial comparisons
Testing On-levodopa vs Testing Off-levodopa: deaths from any cause	0 of 38	0 of 38	76	NCT05487300	Trial comparisons
Testing On-levodopa vs Testing Off-levodopa: serious adverse events	0 of 38	0 of 38	76	NCT05487300	Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42475649	DERIVED	2	PubMed
41734601	DERIVED	1	PubMed
40498549	DERIVED	1	PubMed
39294522	DERIVED	1	PubMed
37962746	DERIVED	1	PubMed
30003579	DERIVED	1	PubMed
28494751	DERIVED	3	PubMed
27538531	DERIVED	3	PubMed
25350981	DERIVED	1	PubMed
24326693	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015914

GET https://conductscience.org/api/diseases/v1/MONDO_0015914/drugs

API reference For AI assistants